Financial Review: Bolt Biotherapeutics (BOLT) and Its Competitors

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Bolt Biotherapeutics to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk.

Volatility and Risk

Bolt Biotherapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics’ peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Institutional and Insider Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Bolt Biotherapeutics and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bolt Biotherapeutics $4.70 million -$33.38 million -0.39
Bolt Biotherapeutics Competitors $768.41 million $11.71 million -18.32

Bolt Biotherapeutics’ peers have higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Bolt Biotherapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics -611.47% -132.36% -53.78%
Bolt Biotherapeutics Competitors -12,224.09% -202.33% -31.23%

Analyst Ratings

This is a summary of current ratings and target prices for Bolt Biotherapeutics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics 1 1 2 0 2.25
Bolt Biotherapeutics Competitors 9923 15317 45694 1603 2.54

Bolt Biotherapeutics currently has a consensus target price of $14.50, suggesting a potential upside of 150.00%. As a group, “Biotechnology” companies have a potential upside of 131.30%. Given Bolt Biotherapeutics’ higher possible upside, research analysts clearly believe Bolt Biotherapeutics is more favorable than its peers.

Dividends

Bolt Biotherapeutics pays an annual dividend of $0.36 per share and has a dividend yield of 6.2%. Bolt Biotherapeutics pays out -2.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.5% and pay out 112.8% of their earnings in the form of a dividend. Bolt Biotherapeutics is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.

Summary

Bolt Biotherapeutics beats its peers on 8 of the 15 factors compared.

Bolt Biotherapeutics Company Profile

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.